Every process that has to do with <em>gathering, storing accessing and analyzing data</em> for a company to make business decisions is referred to as: Business Intelligence.
The business world is faced with many vagaries such as risks and uncertainties. Every business intends to <em>minimize cost and maximize profits</em>. In order to do this, wise and better decisions must be made daily.
For business decisions to be made, <em>predictive views, data mining, process analysis, descriptive analytics, and performance benching</em> are all business intelligence entails.
- Therefore, every process that has to do with <em>gathering, storing accessing and analyzing data</em> for a company to make business decisions is referred to as: Business Intelligence.
Learn more here:
brainly.com/question/21765674
Answer: E. Planning
Explanation:
At the PLANNING STAGE of Strategic Marketing, Hazel should include her goal of a strong ethical environment.
The Planning stage involves penning down goals that one hopes to live up to as well as how they plan to live up to it to ensure a successful implementation.
Putting her goal for an ethical environment in this stage therefore, will ensure that it is a primary goal that is not overlooked during implementation.
Answer:
Minimize startup costs
Raise prices
Get more efficient
Increase the number of sales
Explanation:
<h2>Follow instagrm at --> mvnnyvibes</h2>
Answer:
BrisCor
Budgeting, ethics, pharmaceutical company
a. Referring to the "Standards of Ethical Behavior for Practitioners of Management Accounting and Financial Management,"
none of the preceding items are acceptable to use.
b. I would recommend Jackson to go ahead with the R&D throughout the year to ensure that the drug Vyacon was successfully brought to the market next year before the competitor. He can try to keep to the budget going forward. A budget remains a budget and not the actual. Budget overrun can result. What is important is its effectiveness in achieving business goals.
Explanation:
The announced expectations of third-quarter earnings to Wall Street analysts should not prevent the R&D on the drug Vyacon from continuing, provided Jackson is certain that the envisaged success would be attained. They remain expectations. They are not the actual results of operations for the year. Even if the company's stock price would tumble, it would still recover after the drug had received approval and gone to market, raking in large profits. After all, the projected increase in R&D cost might not result, and the drug Vyacon could be fully developed and ready for the market before year-end, thereby not exceeding its budget.
